Etiometry, the leader in clinical decision-support software for critical care, today announced three new enterprise hospital agreements, further expanding its presence in adult and pediatric ICUs. These deals bring Etiometry’s AI-based clinical intelligence platform to a major healthcare system in a large Midwestern city and renowned healthcare providers in Illinois and Utah – representing a significant addition to Etiometry’s ever-growing customer base and presence across the critical care market.

“We are thrilled to share with these prestigious institutions the transformative power of Etiometry to enhance critical care delivery,” said Shane Cooke, CEO of Etiometry. “Our platform was developed for the ICU in partnership with ICU physicians, so it is specifically designed to empower clinicians with insights to achieve better standardization of care across their ICUs as well as individualization of care at the bedside for the most complex clinical situations in the hospital.”

The Etiometry platform seamlessly aggregates all relevant patient data in near real time and uses proprietary AI to analyze the data in order to uncover the need for escalation and de-escalation of care decisions. Brought together on one screen, this comprehensive view enables ICU care teams the unique opportunity to use data-driven insights to proactively identify potential patient complications, improve overall quality and help support both standardized and individualized care.

Automated reports and stress-free access to data in the platform’s Quality Improvement App, which has supported more than 150 research and quality initiatives, have revolutionized the ability to evaluate adoption, compliance, and effectiveness of quality initiatives, serving as the foundation for a Learning Health System. The abundance of clinical outcomes data associated with Etiometry use, including up to 36% reduction in ICU length of stay (Salvin et al. ‘17 AHA) and 41% reduction in readmissions (Gaies et al, Circulation ’23), are compelling – especially when considering the cost savings associated with these metrics and additional hospital revenue opportunity in terms of the ability to treat more patients.

“More and more healthcare leaders are seeking tangible ways to meet and exceed quality initiatives to enhance care,” said Cooke. “The Etiometry Platform offers a clear path to support these efforts. We look forward to supporting more customers in their pursuit of new and exciting quality benchmarks in high-acuity units.”

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Etiometry Signs Several New Enterprise IDN Agreements first appeared on AI-Tech Park.

Artificial intelligence (AI) promises to transform all aspects of healthcare including clinical research. Emmes Group is rapidly maturing its technology platform, Veridix AI, and Miimansa’s Clinical Entity Modeling technology will serve as a critical building block to accelerate the development of state-of-the-art automated text processing solutions tailored for clinical research.

The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data and enabling text to text transformations such as protocol authoring and medical writing, reducing the time and cost associated with manual data handling and analysis.

“We are excited to partner with Miimansa AI to bring cutting-edge AI technology to the forefront of clinical research,” said Sastry Chilukuri, CEO of Emmes Group. “The clinical entity modeling tools acquired through our partnership will accelerate development and adoption of Emmes Groups’ Gen AI platform, named Concord, to drive faster, better and more efficient clinical trials.”

Dr. Vibhu Agarwal, founder and CEO of Miimansa AI, added, “Teaming up with Emmes Group is a significant milestone for us. Their expertise and comprehensive clinical trial data offer a unique opportunity to apply our advanced AI techniques in real-world settings. Together, we aim to transform the landscape of clinical research, making it faster, more affordable, and ultimately more successful in delivering safe and effective treatments.”

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Emmes Group and Miimansa AI to Boost Generative AI in Research first appeared on AI-Tech Park.

ZeOmega, the leading population health management organization, today launched an integration with HealthFeed, a multi-channel member engagement platform, to deliver critical information, reminders, and personalized messages directly to health plan members’ mobile devices. This integration enhances ZeOmega’s Jiva Member Engagement Navigator with Jiva SMS Text, a TCPA and HIPAA-compliant feature designed to reach high-risk and high-cost member cohorts, ultimately improving engagement and fostering proactive care management.

65% of U.S. adults feel managing healthcare is “overwhelming” and “time-consuming” and engaging members in their healthcare poses a persistent challenge for many health plans. While health-related mobile apps aim to alleviate these hurdles, individuals are reluctant to add more to their devices’ volume of applications. ZeOmega’s integration with HealthFeed enables plans to reach members in real-time, through the convenience of texting, without requiring them to open and manage another mobile app.

Leveraging SMS texting within a closed-loop referral system provides instant and reliable communication, ensuring accessibility and inclusivity for all patients – including those with challenging social determinants of health – and achieves higher engagement rates compared to other communication methods.

“We are excited to integrate the HealthFeed Texting Solution into ZeOmega’s Jiva Member Engagement Navigator, expanding our digital health ecosystem with more user-friendly solutions,” said Suhas Ramachandra, VP, Product Strategy & Innovations at ZeOmega. “This partnership helps our customers deliver the right message to the right member at the right time, positively addressing social determinants of health and driving better outcomes in a cost-effective manner.”

Other notable features and benefits of ZeOmega’s integration with HealthFeed SMS Text include:

• Automation and tracking: This feature streamlines batch messaging and monitors engagement by triggering messages based on configured rules to enhance the efficiency and effectiveness of communication campaigns.
• Clinical intelligence integration: By analyzing comprehensive member data and identifying high-risk populations, this feature enables tailored interventions that support the shift towards value-based care, leading to more effective, evidence-based decision-making.
• Enhanced Member Engagement: The Jiva Member Engagement Navigator suite, including Jiva SMS Text, empowers healthcare organizations to deliver personalized care experiences, delivering messages in the member’s preferred language and channel, improving health outcomes and member satisfaction.

These capabilities allow healthcare teams to leverage an effective outreach channel directly from within their workflows, sending reminders and notifications, and embedding deep links to portals, applications, and educational materials.

“ZeOmega’s Member Engagement Navigator is a game-changer for automated omnichannel member engagement,” said Sai Ganesamoorthi, CEO of HealthFeed. “By combining these two best of breed solutions, ZeOmega can offer its customers a tool that will instantly improve member engagement and empower members to be more proactive about their care – a true win for all healthcare constituents.”

“HealthFeed’s SMS texting platform was the clear choice to enhance our care management portfolio,” said Matt Adamson, VP of Product Planning, ZeOmega. “We’re excited to supercharge our customers’ care management initiatives through this integration.”

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post ZeOmega Launches HealthFeed SMS Texting first appeared on AI-Tech Park.

Advanced subunit vaccine technology, including SuVax and MarVax, to be discussed alongside mRNA and viral vectored vaccine approaches

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Professor Axel Lehrer, University of Hawaiʽi at Mānoa (UHM), will be presenting key data from the Company’s thermostable vaccine technology platform developed in collaboration with UHM, including results from the filovirus vaccine candidates for both Sudan ebolavirus (SuVax) and Marburg marburgvirus (MarVax). The presentation will be given at the upcoming American Society of Microbiology (ASM) Microbe Conference, Atlanta, Georgia, USA, June 13-17, 2024. The presentation will be followed by a panel discussion comparing advanced vaccine technologies and their advantages and disadvantages.

Oral Presentation / Panel Discussion:

Session Title: Immune Responses to Viral Vaccine Platforms: Comparison of Live, mRNA, and Protein Subunit Vaccines on June 17, 2024 from 8:15-10:15 am. The official conference program can be found here.

Oral Presentation Title: Thermostable, adjuvanted protein subunit vaccines reduce logistical concerns and induce durable immunity presented by Axel Lehrer; University of Hawaiʽi at Mānoa, Honolulu, HI on June 17, 2024 at 8:45 AM – 9:15 AM.

Under the Company’s Public Health Solutions business segment, Soligenix is developing thermostabilized subunit vaccines. Thermostabilization is achieved by using a combination of Generally Recognized as Safe (GRAS) excipients and lyophilization (freeze-drying) to yield a single-vial presentation of vaccine that is stable at ambient and higher temperatures and that can be reconstituted with water for injection immediately prior to use. Mono-, bi- and tri-valent vaccine candidates for filoviruses (including Sudan ebolavirus and Marburg marburgvirus) have demonstrated complete protection in non-human primate challenge studies using thermostabilized formulations. Soligenix has recently been granted Orphan Drug Designation for the prevention and post-exposure prophylaxis against both Sudan ebolavirus and Marburg marburgvirus.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Comparing Vaccine Technologies at ASM Microbe Conference first appeared on AI-Tech Park.

Company Reports 150% Growth in Usage of Marketing Automation Platforms

Brandwidth Solutions, a full-service, B2B science-focused marketing communications agency, today announced the launch of its custom marketing ROI platform, LeadInsites^TM, engineered to address the evolving complexities of data tracking and transparency in a variety of B2B industries, including the life sciences, pharmaceutical and technology sectors. This innovative platform provides clients with a tailored solution for integrating and analyzing marketing results from diverse channels in near real-time.

The advent of digital and non-digital marketing avenues has expanded the horizons for marketers, but it has also brought the challenge of aggregating disparate data into a cohesive format. LeadInsites is poised to transform how marketing departments report and track performance, offering a level of customization that aligns with the unique reporting needs of each client.

“Marketing teams have been clear about their struggles – they need to demonstrate transparency and ROI in their results to leadership, and they require the ability to track these results promptly and accurately,” said Debra Harrsch, President and CEO of Brandwidth Solutions. “Our response is a platform that not only consolidates data from myriad channels for a clearer picture of marketing efforts but does so with a speed that matches the pace of today’s business environment. We are able to customize the platform per client specifications and offer graphical data representations for reporting. LeadInsites is a comprehensive view of marketing effectiveness across both digital and non-digital formats.”

One of the standout achievements for Brandwidth in the past year was a 150% increase in clients utilizing marketing automation platforms. This surge is attributed to the development of specialized programs designed to automate lead-nurturing processes, while using diverse content strategies to maintain engagement with prospects at each stage of their journey. Additionally, Brandwidth has implemented robust lead-generation programs to support these nurturing efforts.

In response to client growth and increased demand, the company expanded its workforce by 57% within the year. It has also been recognized as one of the Top Women-Owned Businesses in Greater Philadelphia by the Philadelphia Business Journal for the third consecutive year in 2023.

To explore how Brandwidth’s new LeadInsites platform can streamline marketing data analysis and reporting, and to learn more about marketing solutions that drive sales, please contact Brandwidth Solutions at www.brandwidthsolutions.com.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Brandwidth Launches LeadInsitesTM Marketing ROI Platform first appeared on AI-Tech Park.

HEALWELL AI Inc. (“HEALWELL” or the “Company”) (TSX: AIDX) (OTCQX: HWAIF), an AI and data science company focused on preventative care, is proud to announce its subsidiary Pentavere Research Group (“Pentavere”) have engaged in a partnership and commercial engagement with Takeda Canada Inc. (“Takeda”) to drive real-world evidence analysis for rare diseases, particularly focusing on supporting patients suffering from hereditary angioedema (HAE) with normal C1 inhibitor across Canada. HAE with normal C1 inhibitor is an ultra-rare disease characterized by life-threatening recurrent, unpredictable swelling, and currently does not have any approved treatments.

The scarcity of real-world data on the prevalence and clinical outcomes of these patients poses a significant challenge to the development of novel therapeutic agents. Recognizing this critical unmet need, Takeda has collaborated with Pentavere and top HAE specialists across Canada to support research into the gaps in treatment guidelines and approved therapies for these patients. This innovative research collaboration has resulted in the generation of one of the largest cohort datasets globally of hereditary angioedema with normal C1 inhibitor patients.

Jefferson Tea, PhD, Vice President, Medical and Scientific Affairs, Takeda. “We are pleased to be partnering with Pentavere as this study is an ongoing example of our steadfast commitment to working with leading data science companies to drive innovation and assist patients in their care journey. By harnessing the power of AI and data analytics, and collaborating with experts in these fields, we aim to advance the understanding and management of rare diseases like HAE, supporting patients and their families in their care journey, and ultimately improving patient outcomes.”

Dr. Durhane Wong-Rieger CEO, of Canadian Organization for Rare Disorders stated, “When the number of patients is small, the use of AI and data analytics to understand the whole of their patient journey to inform diagnosis and best management is a game changer that could prove as impactful as decoding the human genome. We are extremely grateful to Pentavere, HEALWELL, and Takeda for investing in this initiative and for including CORD as a partner to drive to a vision where this is available for all patients.”

Aaron Leibtag, CEO of Pentavere, commented, “We are incredibly proud of our ongoing partnership with Takeda and how it has grown and evolved since winning the Takeda Canada Innovation Challenge to accelerate rare disease diagnosis and care. This collaboration not only underscores the significance of Pentavere’s technology, but also highlights the transformative impact data science can have in healthcare. Together, we are breaking new ground in real-world evidence analysis for rare diseases, reaffirming our commitment to driving innovation and improving patient outcomes.”

The comprehensive dataset compiled through this partnership will play a pivotal role in filling the real-world data gap on the burden of disease and clinical outcomes for HAE with normal C1 inhibitor patients. By leveraging advanced data science techniques, Pentavere analyzed this dataset as part of the PROSPECT study to extract actionable insights that can inform treatment strategies and improve patient outcomes. A manuscript and an abstract on the PROSPECT study data are currently under preparation and will be submitted for publication soon.

Pentavere unlocks a deeper understanding of patient treatment needs by enabling effortless data access and rapid insight generation. DARWEN has the capacity to harness electronic medical record data and utilizes advanced large language models to analyze disparate and siloed clinical notes that are otherwise very challenging to access, allowing meaningful solutions to some of healthcare’s biggest challenges and delivering on the current need for medicine to become more personalized.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Pentavere Partners Takeda to Support Evidence Analysis for Patients first appeared on AI-Tech Park.

Over the past two years, ConcertAI has assembled the deepest and largest multi-modal oncology data repository in the industry, representing more than 8 million patients. This effort was significantly accelerated in December 2023, when the American Society of Clinical Oncology (ASCO) CancerLinQ program became a ConcertAI initiative under a long-term cooperation agreement with ASCO. In collaboration with molecular diagnostic partners and its radiological imaging business, TeraRecon, ConcertAI has established a research capability that spans genomic, transcriptomic, digital pathology, digital radiology, clinical, and social determinants of health data. This comprehensive data set covers all 50 states, offering the broadest representativeness and generalizability of any clinical data source, and forms the foundation for a range of next-generation AI models and AI-powered services. In January, the company announced its CARA AI platform, which underpins a new class of AI SaaS solutions powered by the company’s multi-modal data solutions and supports healthcare providers, research sites, and life science companies. 

As part of the collaboration, ConcertAI’s efforts to drive leading intelligence and insight in oncology research and treatment will be supported by NVIDIA’s AI expertise and infrastructure. This includes incorporating the Meta Llama 3 NIM, announced at Computex today, to drive key LLM workloads inside ConcertAI’s suite of solutions. The focus of ConcertAI’s work with NVIDIA will be on large-scale clinical data processing, multi-agent models, clinical foundation models, and related solutions that enable domain-specific AI and broad application generative AI to interoperate with unprecedented precision.

Key initiatives under this collaboration include:

• High-performance AI models for clinical development solutions: This initiative will leverage NVIDIA NIMs to provide scalable, high-performance AI model deployment with low latency, enhancing flexibility, interoperability, and cost efficiency within the ConcertAI CARA AI platform. The integration will support clinical trial patient matching, protocol automation, and research site co-pilots with real-time analytics and model management for large-scale AI applications.
• Large-scale processing of multi-modal data: This initiative will harness NVIDIA CUDA-X microservices to accelerate ConcertAI’s large-scale data processing pipelines, significantly enhancing the largest curated oncology data set globally. By leveraging CUDA-X’s advanced computing capabilities, ConcertAI will achieve faster data processing speeds and efficiency, enabling more effective management of its vast oncology data.
• Development of precision oncology and medical large language models (LLMs): These foundation models, trained on ConcertAI’s industry-leading multi-modal data, will support advanced translational simulations to guide novel, first-in-human studies, clinical trial simulations and design optimizations, clinical decision augmentation support for clinical pathways, and identification of beneficial diagnostic and treatment approaches.

“Life sciences research and precision medicine both involve complex decisions based on many types of data and time points,” said Jeff Elton, PhD, CEO of ConcertAI. “For any single patient, we may have billions of unique data points, and we may be looking across millions of records, making this a domain where AI can enable insights not possible with prior technologies or methodologies. We are thrilled to work with NVIDIA to push the boundaries of what AI can achieve in oncology translational research, clinical development, and care. Our collaboration will bring unprecedented precision and new levels of efficiency to our customers’ development of new medicines, helping accelerate the improvement of outcomes for patients with the greatest unmet medical needs.”

“AI offers incredible potential to transform how medicines are designed and developed, and bringing generative AI tools to improve clinical trials is a groundbreaking and necessary step,” said Kimberly Powell, VP of Healthcare at NVIDIA. “Integrating NVIDIA’s NIM’s into ConcertAI’s SaaS and extensive multi-modal data platform will revolutionize clinical trial design and outcome prediction.”

This collaboration underscores ConcertAI’s commitment to harnessing the power of AI to drive innovation in healthcare and improve patient outcomes worldwide. Initial benefits from the collaboration will be accessible in the CARA AI cloud and solutions in Q3 of 2024.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post ConcertAI to Clinical Development Solutions in Collaboration with NVIDIA first appeared on AI-Tech Park.

Today Domo (Nasdaq: DOMO) announced Regional One Health Solutions, LLC, as a channel partner in the company’s recently updated and expanded partner program. Focused on helping healthcare organizations harness the power of data and Domo to improve patient care, advance operational efficiencies and inform decision-making, Regional One Health Solutions couples its deep healthcare expertise with Domo to drive meaningful operational and patient outcomes for its customers nationwide.

Regional One Health Solutions is the healthcare consultancy division of Regional One Health, a level-1 trauma center located in Memphis, Tennessee. As a premier healthcare organization, Regional One Health is transforming the healthcare industry through informed, data-driven decisions. With Domo, Regional One Health created robust, interactive metrics dashboards that track progress towards organizational KPIs such as length of stay, harm events, patient satisfaction scores, turnover, streamlined care practices, and expense and labor costs. In 2023, the two organizations received a Nucleus Research ROI Award for achieving a total ROI of 190% for this impactful work.

Following the organization’s successful outcomes, Regional One Health worked with Domo to develop the Healthcare Metrics Quick Starter App, centered on helping all healthcare leaders connect clinical and nonclinical data to monitor KPIs and improve operations. Most recently, Regional One Health Solutions launched an extensive portfolio of use cases to allow healthcare organizations to see data in action in clinical, operational, and financial areas and facilitate a quicker start to their Domo journey.

“Regional One Health is disrupting the health care industry, making significant impacts in operational efficiency, data transformation, and patient care and satisfaction. We’re thrilled that Regional One Health Solutions will bring its expertise to the wider healthcare industry and are grateful to have them not only as a valued customer but also as a significant member of our channel partner program,” said RJ Tracy, SVP of Partners, Strategic Development and Channel, Domo.

“Our work with Domo has been pivotal to our organizations’ goals of improving patient, operational, and financial outcomes. At the core of this success has been a focus and specialization on leveraging data and Domo to identify issues and impact change,” said Jani Radhakrishnan, Principal and CEO, Regional One Health Solutions. “Being part of Domo’s channel program will help our organization drive greater change in the healthcare industry, with the ultimate goal of improving the lives of patients nationwide.”

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Domo and Regional One Health Solutions Harness the Power of Data first appeared on AI-Tech Park.

Highlights

• Enlitic brings its development schedule forward by 18 months with the release of Ensight 2.0 (“Ensight”)
• Ensight expands the suite of available use cases through an integrated framework
• Ensight will continue to accelerate commercial traction in the second half of 2024

Enlitic, Inc., (ASX: ENL)(“the Company”), a leading innovator in data standardization, has released Ensight to the market. The newest version of its data standardization software framework was originally planned for the second half of 2025.

Ensight generates standardized study and series descriptions from pixel and metadata of medical images and deidentifies Protected Health Information (PHI) found in these images. This functionality enables healthcare providers to realize value from an increasing number of use cases that improve the data quality, such as identifying laterality conflicts or contrast billing discrepancies. Using natural language processing and computer vision, Ensight improves radiologist reporting workflows, enhances data quality, and creates new revenue opportunities for our customers.

The Ensight framework lays the foundations for expanding capabilities as outlined by the product roadmap, introducing key essential components. Ensight integrates the ENDEX data standardization module and the ENCOG anonymization module into a unified software framework coupled with key infrastructural components required to deliver the planned common data model. Enhancements in the artificial intelligence (AI) data models, DICOM SR (Structured Reporting) and HL7 outputs (Data Sharing) alongside configurable standardized outputs highlight some of the notable new features being introduced.

Michael Sistenich, CEO of Enlitic, said “We have been anticipating this release and have focused the organization to deliver these powerful enhancements ahead of schedule. The benefit of this release will enable pending deployments and bring real value to our customers, while also setting the stage for us to deliver on our future roadmap. Healthcare has always been challenged to transform the massive amounts of imaging data it produces into actionable insights. Our solutions are designed to address these long-standing challenges and contribute to delivering better outcomes for our customers.”

Industry analysts report that despite over 50% of healthcare executives recognizing the critical importance of data utilization, more than 97% of data generated by healthcare providers remains locked away. Meanwhile, investments in data solutions must strike a balance, providing immediate benefits while paving the way for future applications. Enlitic understands these challenges and remains steadfast in its commitment to developing solutions that directly tackle these issues head-on.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Enlitic® Announces New Version of Data Standardization Software first appeared on AI-Tech Park.

CLEW, a clinical intelligence and predictive surveillance company, today announced the general availability of its FDA-cleared, AI-driven, intelligent clinical surveillance platform. Built upon proprietary, machine-learning derived prediction models and rules-based best practices, the CLEW platform offers health systems an early identification of a patient’s risk of deterioration.

CLEW initially introduced its system of AI-generated prediction models in 2019 to support critical care and telemedicine operations, aiming to enhance patient care in virtual intensive care units (VICUs or Tele-ICUs). Implemented in numerous critical care departments across the United States, including Penn State Health, the system quickly demonstrated its efficacy and CLEW promptly responded to customer demands by expanding its platform to areas such as the emergency department, medical/surgical floors, perioperative suites, and specialty care units.

“As we navigate the complexities of modern healthcare, AI-derived systems emerge as a beacon of innovation, transforming our approach to care delivery,” Paul Roscoe, CLEW CEO shared. “When delivered with meticulous regulatory oversight, AI can unlock new possibilities for precision medicine, early detection, and personalized treatments. Our commitment to integrating AI-driven prediction models into healthcare reflects our dedication to enhancing patient outcomes, driving efficiencies, and ultimately, saving lives.”

Equipped with these advanced clinical insights, caregivers can focus on delivering exceptional patient care at the highest level of their licensure. The CLEW system empowers care teams to intervene proactively in identifying high-risk patients up to eight hours before physiological signs and other monitoring systems would indicate. This leads to lower mortality rates, decreased complications, and fewer readmissions. As a result, proactive and timely care mitigates unforeseen bottlenecks, reduces length of stay and improves overall capacity.

In addition to CLEW’s robust prediction models, its platform includes built-in, best practice clinical protocols. They are easily customizable, allowing health systems to add their own standard practices for consistent deployment of specific care plans. With its NotifyMe solution, caregivers can receive tailored multi-parameter smart alerts, specifically designed to pinpoint urgent and complex clinical scenarios. Clinicians have the flexibility to determine which attributes and clinical criteria are crucial for monitoring and personalize the configuration.

The CLEW platform also includes prediction-driven clinician-centric tools designed to reduce nursing fatigue, including a real-time, priority-driven patient worklist developed in collaboration with nurses at Penn State Health. Since going live with the platform, the critical care team at Penn State has integrated the use of CLEW into their daily workflow.

A recent peer-reviewed study published in CHEST Journal, notably found that predictions from the CLEW platform were at least five times more accurate than alerts from the leading telemedicine system and generated 50 times fewer alarms than other monitoring systems. For more information about that study, click here.

For more information about the CLEW system, contact the CLEW team.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post CLEW’s Intelligent Clinical Surveillance Platform generally available first appeared on AI-Tech Park.